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Abstract: Salicylaldehyde 2-chlorobenzoyl hydrazone (H2LASSBio-466), salicylaldehyde 
4-chlorobenzoyl hydrazone (H2LASSBio-1064) and their complexes [Zn(LASSBio-
466)H2O]2 (1) and [Zn(HLASSBio-1064)Cl]2 (2) were evaluated in animal models of 
peripheral and central nociception, and acute inflammation. All studied compounds 
significantly inhibited acetic acid-induced writhing response. Upon coordination the anti-
nociceptive activity was favored in the complex 1. H2LASSBio-466 inhibited only the first 
phase of the formalin test, while 1 was active in the second phase, like indomethacin, 
indicating its ability to inhibit nociception associated with the inflammatory response. 
Hence coordination to zinc(II) altered the pharmacological profile of H2LASSBio-466. 
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H2LASSBio-1064 inhibited both phases but this effect was not improved by coordination. 
The studied compounds did not increase the latency of response in the hot plate model, 
indicating their lack of central anti-nociceptive activity. All compounds showed levels of 
inhibition of zymosan-induced peritonitis comparable or superior to indomethacin, 
indicating an expressive anti-inflammatory profile. 
Keywords: acylhydrazones; zinc(II) complexes; analgesic activity; anti-inflammatory 
activity 
 
1. Introduction 
Inflammation is a response of the immune system to physical and/or chemical and/or biological 
injury, understanding by injury any process able to cause tissue or cellular damages. The types of 
inflammation (i.e. acute or chronic) differ by cause, mechanism, outcome, and intensity. It is well 
known that while acute inflammation has a physiological role in normal circumstances, chronic 
inflammation exerts detrimental effects on the functional status of cells and tissues. As a consequence 
inflammatory processes take part in a huge number of diseases such as atherosclerosis, Alzheimer 
disease, Parkinson disease, cancer, asthma, arthritis and so on [1-3]. 
Zinc is one of the most prevalent trace elements in the human body. It has been shown to be 
essential to the structure and function of a large number of macromolecules and for a variety of 
enzymatic reactions, which mediate a wide range of physiological processes [4,5]. These include 
production of collagen and other extracellular matrix proteins, modulation of immunoregulatory  
(e.g., T and B lymphocytes, macrophages, and antigen-presenting dendritic cells) and inflammatory 
(e.g., eosinophils, neutrophils, and mast cells) cells function. As a consequence, zinc may be considered 
an important immunoregulatory agent with anti-apoptotic and anti-inflammatory activities [6]. 
Figure 1. Generic structure of salicylaldehyde 2-chlorobenzoyl hydrazone (H2LASSBio-
466) and its regioisomer salicylaldehyde 4-chlorobenzoyl hydrazone (H2LASSBio-1064). 
 
 
In the context of a research program that aims to contribute to the discovery of new anti-
inflammatory and analgesic drug candidates, we describe the synthesis of zinc(II) complexes with 
salicylaldehyde 2-chlorobenzoyl hydrazone (H2LASSBio-466) and its regioisomer salicylaldehyde 4-
Molecules 2011, 16              
 
6904
chlorobenzoyl hydrazone (H2LASSBio-1064) (Figure 1), together with a pharmacological evaluation 
of all acylhydrazones and zinc(II) complexes in animal models of peripheral and central nociception 
and acute inflammation. 
2. Results and Discussion 
2.1. Formation of the Zinc(II) Complexes 1 and 2 
Microanalyses and molar conductivity data are compatible with the formation of [Zn(LASSBio-
466)H2O] and [Zn(HLASSBio-1064)Cl]. In the first compound a di-anionic acylhydrazone is attached 
to the metal center upon deprotonation at N(2)-H and O(1)-H. The remaining coordination site is 
occupied by a water molecule, as indicated by the infrared spectrum of the compound (Section 2.3). In 
the second, a mono-anionic acylhydrazone is attached to the metal upon deprotonation at O(1)-H, 
together with a chloride ion. 
Upon recrystallization of [Zn(HLASSBio-1064)Cl] in 1:9 DMSO-acetone, crystals of 
[Zn2(LASSBio-1064)2(H2O)2]·[Zn2(LASSBio-1064)2(DMSO)4] were obtained. The compound 
consists of two center symmetric binuclear zinc(II) complexes hosted in the same lattice, as previously 
reported by some of us [7]. We had also obtained [Zn(LASSBio-1064)]2, which is a phenoxo-bridged 
dimer since the monomer would contain zinc(II) with coordination number three, which is very 
unlikely [7]. Hence [Zn(HLASSBio-1064)Cl] most probably also exists as a dimer, [Zn(HLASSBio-
1064)Cl]2. 
We now obtained [Zn(LASSBio-466)(H2O)], in which a water molecule occupies the fourth 
coordination position, like in the first center symmetric unit of [Zn2(LASSBio-
1064)2(H2O)2]·[Zn2(LASSBio-1064)2(DMSO)4]. Therefore, [Zn(LASSBio-466)(H2O)] is also 
probably a phenoxo-bridged dimer, [Zn(LASSBio-466)(H2O)]2. Considering that dimerization is 
favored in this class of compounds [7], the zinc(II) complexes are hereafter formulated as 
[Zn(LASSBio-466)(H2O)]2 (1) and [Zn(HLASSBio-1064)Cl]2 (2). 
Figure 2. Molecular plot of LASSBio-466 showing the labeling scheme of the non-H 
atoms and their displacement ellipsoids at the 50% probability level. 
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2.2. Crystal Structure of H2LASSBio-466 
Crystal data and refinement results are summarized in Table 1. Figure 2 is an ORTEP [8] drawing 
of the molecule and Table 2 shows the corresponding intra-molecular bond distances and angles.  
Table 1. Crystal data and structure solution methods and refinement results for 
salicylaldehyde 2-chlorobenzoyl hydrazone (H2LASSBio-466). 
Compound H2LASSBio-466 
Empirical Formula C14H11ClN2O2 
Formula Weight 274.70 
Temperature, K 294(2) 
Crystal System Monoclinic 
Space Group P21/c 
Unit cell dimensions 
a, Å 9.889(1) 
b, Å 13.360(2) 
c, Å 10.079(1) 
α, ° 90 
β, ° 93.10(1) 
γ, ° 90 
Volume, Å3 1329.7(3) 
Z, Density calc., Mg/m3 4, 1.372 
Absorption coefficient, mm−1 0.286 
F(000) 568 
Crystal size, mm 0.20 × 0.12 × 0.08 
Crystal color / shape Colorless / prism 
θ range for data coll. 3.05 to 24.08º 
Index range 
−10 ≤ h ≤11 
−15 ≤ k ≤ 15 
−11 ≤ l ≤ 11 
Completeness, θ = 26.37° 99.6 % 
Max. / min. transmission 0.977 / 0.945 
Goodness–of–fit on F2 1.016 
Reflec. collect./unique (Rint) 5646/2095 (0.032) 
Observed reflections [I > 2σ(I)] 1612 
Weights, w [σ2(Fo2) + (0.088P)2 + 0.22P]-1 P = [Max((Fo2,0) + 2Fc2]/3 
Data / restraints / parameters 2095 / 0 / 184 
Final R indexesa [I > 2σ(I)] R1 = 0.0474, wR2 = 0.1296 
R indices (all data) R1 = 0.0637, wR2 = 0.1479 
Extinction coefficient 0.07(1) 
Larg. peak & hole, e Å−3 0.180 / -0.246 
a R indices defined as: R1=Σ||Fo|-|Fc||/Σ|Fo|, wR2=[Σw(Fo2-Fc2)2/Σw(Fo2)2]1/2. 
 
The phenyl rings show a delocalized bonding structure, with C-C distances ranging from 1.370(3) 
to 1.388(3) Å for the chlorine-containing phenyl, where d(Cph-Cl) = 1.724(3) Å, and from 1.359(4) to 
1.400(3) Å for the phenol ring, where d(Cph-OH) = 1.353(3) Å. We found for the carbonyl C(8)=O(2) 
and C(7)=N(1) groups distances of 1.226(2) and 1.272(3) Å, respectively, as expected for formal 
double bonds. The N(1)-N(2) length of 1.376(3) Å agrees with the single bond character of this link. 
The molecule conformation is stabilized by a strong intra-molecular O-H…N bond [d(O(1)···N(1)) = 
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2.632 Å, ∠(O(1)-H(1)···N(1)) = 145.7°]. As shown in Figure 2 the hydrazone adopts the E 
configuration in the crystal state. 
Table 2. Bond lengths [Å] and angles [°] for salicylaldehyde 2-chlorobenzoyl hydrazone 
(H2LASSBio-466). 
Atoms Bond lengths (Å) Atoms Angles (°) 
Cl-C(10) 1.724(3) O(2)-C(8)-C(9) 123.2(2) 
O(1)-C(1) 1.353(3) N(1)-C(7)-C(2) 121.1(2) 
O(2)-C(8) 1.226(3) N(2)-C(8)-C(9) 114.7(2) 
N(1)-N(2) 1.376(3) N(1)-N(2)-C(8) 118.6(2) 
N(1)-C(7) 1.272(3) N(2)-N(1)-C(7) 117.2(2) 
N(2)-C(8) 1.346(3) C(1)-C(2)-C(3) 118.3(2) 
C(1)-C(2) 1.400(3) C(1)-C(2)-C(7) 122.2(2) 
C(1)-C(6) 1.384(4) C(1)-C(6)-C(5) 120.5(3) 
C(2)-C(3) 1.390(3) C(2)-C(1)-C(6) 119.7(2) 
C(2)-C(7) 1.445(3) C(2)-C(3)-C(4) 121.1(3) 
C(3)-C(4) 1.374(4) C(3)-C(4)-C(5) 119.5(3) 
C(4)-C(5) 1.371(5) C(3)-C(2)-C(7) 119.5(2) 
C(5)-C(6) 1.359(4) C(4)-C(5)-C(6) 120.8(3) 
C(8)-C(9) 1.494(3) C(8)-C(9)-C(10) 122.4(2) 
C(9)-C(10) 1.393(3) C(8)-C(9)-C(14) 119.9(2) 
C(9)-C(14) 1.388(3) C(9)-C(10)-Cl 120.8(2) 
C(10)-C(11) 1.381(4) C(9)-C(10)-C(11) 121.1(3) 
C(11)-C(12) 1.376(4) C(9)-C(14)-C(13) 121.5(3) 
C(12)-C(13) 1.371(4) C(10)-C(9)-C(14) 117.6(2) 
C(13)-C(14) 1.370(3) C(10)-C(11)-C(12) 119.5(3) 
  C(11)-C(10)-Cl 118.1(2) 
  C(11)-C(12)-C(13) 120.3(3) 
  C(12)-C(13)-C(14) 119.9(3) 
  O(1)-C(1)-C(2) 122.4(2) 
  O(1)-C(1)-C(6) 118.0(2) 
  O(2)-C(8)-N(2) 122.1(2) 
 
The solid is further stabilized by a medium-strength inter-molecular N-H···Ocarbonyl bond 
[d(N(2)···O(2)) = 2.885 Å, ∠(N(2)-H(2)···O(2’)) = 166.2°] between neighboring molecules, symmetry-
related to each other through a glide plane, involving the imine group of a molecule as a donor and the 
carbonyl oxygen of the other as an acceptor. This gives rise to a polymeric structure that extends along 
the crystal c-axis (see Figure 2). 
2.3. Spectroscopic Characterization 
The vibrations at 3450–3436 cm−1 in the infrared spectra of the free acylhydrazones attributed to 
ν(O-H) disappear in those of the complexes, in accordance with deprotonation of the phenol group [9]. 
The ν(C=O) absorption at 1657 cm−1 in the spectrum of the H2LASSBio-466 was not found in the 
spectrum of the complex 1, indicating coordination of an enolate oxygen [10,11]. The ν(C=O) 
absorption at 1676 cm−1 in the spectrum of the H2LASSBio-1064 shifts to 1618 cm−1 in the spectrum 
of 2, indicating coordination through the carbonyl oxygen [10-13]. The vibrations attributed to ν(C=N) 
at 1625 and 1624 cm−1 in the infrared spectra of the hydrazones shift to 1614 and 1611 cm−1, 
respectively, in the spectra of the complexes, in agreement with coordination of the azomethine 
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nitrogen [10-13]. A new absorption at 1604 cm−1 in the spectrum of complex 1 was attributed to the 
ν(OH2) vibration. 
The NMR spectra of the acylhydrazones and their zinc(II) complexes were recorded in DMSO-d6. 
The 1H resonances were assigned on the basis of chemical shifts and multiplicities. The carbon type 
(C, CH) was determined by using distortionless enhancement by polarization transfer (DEPT 135) 
experiments. The assignments of the protonated carbons were made by 2D heteronuclear multiple 
quantum coherence experiments (HMQC). 
The signals of all hydrogens and carbons are duplicated in the 1H- and 13C-NMR spectra of 
H2LASSBio-466, indicating the presence of the E and Z configurational isomers in the DMSO-d6 
solution. In fact, two N(2)-H signals were observed at δ 11.05 and 9.84 ppm, which were attributed to 
the Z and E isomers, respectively. In the first N(2)-H is hydrogen bonded to the phenol oxygen, while 
in the latter it is hydrogen bonded to the solvent [10-13]. Only one signal was found for each hydrogen 
and each carbon in the 1H- and 13C-NMR spectra of H2LASSBio-1064. These signals are compatible 
with the presence of the E configurational isomer. 
Only one signal was observed for each hydrogen and each carbon in the spectra of complexes 1-2. 
The O(1)-H signals were absent in the spectra of all complexes, in agreement with deprotonation and 
formation of a phenolate group. In the spectrum of 1 the N(2)-H signal disappears, suggesting 
deprotonation of the hydrazone upon coordination. Hence in 1 a di-anionic hydrazone ligand is 
attached to the zinc(II) center. In the spectrum of 2 the N(2)-H signal was observed, according with the 
presence of a mono-anionic hydrazone ligand. In the 1H-NMR spectra of the complexes the signals of 
all hydrogens undergo significant shifts in relation to their positions in the free hydrazones. Similarly, 
the signals of C=N, C=O and the phenol carbons undergo significant shifts in complexes 1 and 2, 
indicating coordination through the Ophenol-N-O chelating system. Hence in 1-2 the hydrazones adopt 
the E configuration.  
2.4. Anti-Nociceptive Activity of H2LASSBio-466, H2LASSBio-1064, [Zn(LASSBio-466)H2O]2 (1) and 
[Zn(HLASSBio-1064)Cl]2 (2)  
The anti-nociceptive profiles of the free ligands H2LASSBio-466, H2LASSBio-1064 and their 
zinc(II) complexes 1 and 2 were evaluated using three well-accepted pain models, namely acetic acid-
induced writhing, formalin-induced nociception and hot plate test. The acetic acid-induced abdominal 
writhing and hot-plate test have been reported to be useful to investigate peripheral and central 
activity, respectively, while the formalin-induced nociception is valuable to detect both effects, 
including inflammatory pain. 
All compounds were evaluated at a dose of 100 μmol/kg (p.o). Indomethacin, a COX-1 selective 
inhibitor (100 μmol·kg−1, p.o.) and dipyrone, a COX-3 selective inhibitor (100 μmol·kg−1, p.o.) were 
used as standard drugs in the peripheral nociception models, while morphine (15 μmol·kg−1, i.p.) was 
used as standard in the hot-plate test. The analgesic activity of H2LASSBio-466, its regioisomer 
H2LASSBio-1064, and their complexes [Zn(LASSBio-466)H2O]2 (1) and [Zn(HLASSBio-1064)Cl]2 
(2) was initially evaluated employing the acetic acid-induced abdominal writhing model in mice and 
compared with those of the standards [14].  
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As shown in Table 3, all compounds produced marked inhibition of acetic acid-induced writhing 
response. However, the anti-nociceptive activity appears to have been favored by complex formation 
in the case of complex 1, given its increased activity compared to the H2LASSBio-466 free ligand.  
Table 3. Effect of H2LASSBio-466, its regioisomer H2LASSBio-1064, their zinc(II) 
complexes, indomethacin and dipyrone (100 µmol·kg−1, p.o.) on the 0.6% acetic acid-
induced abdominal constrictions in mice, for a period of 25 min. 
Substance n Writhing number Mean ± S.E.M. 
% of inhibition 
Mean ± S.E.M. 
Control 6 37.5 ± 1.4 ___ 
Indomethacin 6 6.0 ± 3.1 ** 84.0 ± 8.3 ** 
Dipyrone 6 8.3 2.7 ** 77.8 ± 7.2 ** 
H2LASSBio-466 6 14.8 ± 2.2 ** 60.4 ± 6.0 ** 
H2LASSBio-1064 6 7.0 ± 1.1 ** 81.3 ± 3.0 ** 
[Zn(LASSBio-466)H2O]2 (1) 6 6.6 ± 1.4 ** 82.3 ± 3.7 ** 
[Zn(HLASSBio-1064)Cl]2 (2) 6 10.8 ± 2.3 ** 70.9 ± 6.2 ** 
Data are expressed as mean ± S.E.M. Statistical differences between the treated and the control 
groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the levels of 
significance in comparison with control groups, ** P < 0.01. 
 
The neurogenic and inflammatory pain was evaluated using the formalin test and analyzing the first 
and the second phases of the nociceptive response, respectively [15]. In this model, H2LASSBio-466 
was effective in inhibiting only the first phase, while [Zn(LASSBio-466)H2O]2 (1), like indomethacin, 
was active in the second phase, indicating its ability to inhibit nociception associated with 
inflammatory response (Table 4). H2LASSBio-1064 was able to inhibit both neurogenic and 
inflammatory phases anticipating a distinct pharmacological profile. However this effect decreases on 
coordination to zinc(II) in complex 2. These results suggest that coordination seems to be a good 
strategy to improve the antinociception profile of the prototype H2LASSBio-466 associated with an 
inflammatory pain. 
Table 4. Effect of prototypes H2LASSBio-466, H2LASSBio-1064, their zinc(II) complexes 
and indomethacin (100 µmol·kg−1, p.o.) on formalin (2.5%) test in mice. 
Substance n Phase 1 Mean ± S.E.M. 
Phase 2 
Mean ± S.E.M. 
% of inhibition (Mean ± S.E.M.) 
Phase 1 Phase 2 
Control 5 54.8 ± 2,3 227.6 ± 22.7 — — 
Indomethacin 5 57.1 ± 8.5 115.9 ± 3.3 * 0 49.1 ± 1.4 * 
H2LASSBio-466 5 29.3 ± 8.3 ** 182.4 ± 17.4 46.5 ± 8.3 ** 19.8 ± 9.7 
H2LASSBio-1064 5 25.7 ± 4.9 * 117.0 ± 19.1 * 53.1 ± 8.9 * 48.5 ± 8.4 * 
[Zn(LASSBio-466)H2O]2 (1) 5 40.6 ± 12.7 142.8 ± 23.1 * 25.9 ± 15.7 37.3 ± 10.1 * 
[Zn(HLASSBio-1064)Cl]2 (2) 5 39.6 ± 7.8 161.3 ± 36.0 27.7 ± 13.1 29.2 ± 13.9 
Data are expressed as mean ± S.E.M. Statistical differences between the treated and the control 
groups were evaluated by test t and Mann-Whitney tests and the asterisks denote the levels of 
significance in comparison with control groups, * P < 0.05 and ** P < 0.01. 
 
In order to investigate an occasional central anti-nociceptive activity for prototypes H2LASSBio-
466, H2LASSBio-1064 and their zinc(II) complexes, the studied compounds were evaluated in the hot 
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plate test using morphine (15 µmol·kg−1, i.p.) as standard [16]. As shown in Table 5, these compounds 
did not increase the latency of response significantly, showing that they do not present activity in the 
supra-spinal analgesia, while morphine induced a marked increase in the latency of the animals at  
60 min (9.0 ± 1.6 s), 90 min (7.4 ± 0.8 s), 120 min (5.3 ± 0.8 s) and 150 min (2.5 ± 0.2 s). These 
results indicate that the studied compounds do not have any central anti-nociceptive activity. 
Table 5. Time course effect of prototypes H2LASSBio-466, H2LASSBio-1064, their 
zinc(II) complexes (100 µmol·kg−1, p.o.) and morphine (15 µmol·kg−1, i.p.) on hot-plate 
test in mice. 
Substance n 
Mean ± S.E.M. 
0 min 60 min 90 min 120 min 150 min 
Control 6 2.8 ± 0.2 2.9 ± 0.3 1.6 ± 0.2 2.3 ± 0.40 1.7 ± 0.1 
Morphine 6 1.8 ± 0.5 9.0 ± 1.6 * 7.4 ± 0.8 * 5.3 ± 0.8 * 2.5 ± 0.2 
H2LASSBio-466 6 2.1 ± 0.21 2.3 ± 0.4 2.1 ± 0.2 2.2 ± 0.2 2.6 ± 0.1 
H2LASSBio-1064 6 1.7 ± 0.18 2.6 ± 0.2 2.1 ± 0.2 2.5 ± 0.3 3.5 ± 0.3 
[Zn(LASSBio-466)H2O]2 (1) 6 2.1 ± 0.2 4.2 ± 0.8 2.4 ± 0.6 3.6 ± 0.6 5.4 ± 1.2 
[Zn(HLASSBio-1064)Cl]2 (2) 6 1.5 ± 0.1 2.0 ± 0.5 2.3 ± 0.5 2.9 ± 1.0 1.9 ± 0.2 
Data are expressed as mean ± S.E.M. Statistical differences between the treated and the control 
groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the levels of 
significance in comparison with control groups, * P < 0.05. 
 
To better assess the potential anti-inflammatory activity of the free acylhydrazones and their 
zinc(II) complexes, the zymosan-induced peritonitis assay was performed [17]. As seen in Table 6, all 
compounds showed some level of inhibition in this cell migration model comparable or superior to 
indomethacin. 
Table 6. Effect of prototypes H2LASSBio-466, H2LASSBio-1064, their zinc(II) complexes 
and indomethacin (100 µmol·kg−1, p.o.) on the zymosan-induced peritonitis in mice. 
Substance n Cell Number × 10
6/mL 
Mean ± S.E.M. 
% of inhibition 
Mean ± S.E.M. 
Control 7 38.0 ± 1.0 ___ 
Saline 7 5.0 ± 0.8 ___ 
Indomethacin 7 17.7± 1.0 ** 53.4 ± 2.7 ** 
H2LASSBio-466 7 11.4 ± 1.4 ** 70.0 ± 3.8 ** 
H2LASSBio-1064 7 8.4 ± 0.9 ** 77.8 ± 2.4 ** 
[Zn(LASSBio-466)H2O]2 (1) 7 10.7 ± 1.8 ** 71.8 ± 4.9 ** 
[Zn(HLASSBio-1064)Cl]2 (2) 7 13.4 ± 1.5 ** 64.7 ± 4.0 ** 
Data are expressed as mean ± S.E.M. Statistical differences between the treated and the control 
groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the levels of 
significance in comparison with control groups, ** P < 0.01. 
 
In fact, H2LASSBio-466, H2LASSBio-1064, [Zn(LASSBio-466)H2O]2 and [Zn(HLASSBio-
1064)Cl]2, presented 70.0%, 77.8%, 71.8% and 64.7% of inhibition, respectively, while indomethacin 
inhibited cell-migration by 53.4%. 
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3. Experimental 
3.1. General 
All common chemicals were purchased from Aldrich and used without further purification. Partial 
elemental analyses were performed on a Perkin Elmer CHN 2400 analyzer. A YSI model 31 
conductivity bridge was employed for molar conductivity measurements (1 × 10−3 mol L−1, DMF). 
Infrared spectra (4000-400 cm-1) were recorded on a Perkin Elmer FT-IR Spectrum GX spectrometer 
using KBr plates. NMR spectra were obtained with a Bruker DPX-200 Avance (200 MHz) 
spectrometer using DMSO-d6 as the solvent and TMS as internal reference. 
3.2. Synthesis of H2LASSBio-466 and H2LASSBio-1064 
The synthesis of H2LASSBio-466 and H2LASSBio-1064 were performed using a previously 
described methodology [18]. Briefly, salicylaldehyde (2-hydroxybenzaldehyde) was added to a 
solution of 2-chlorobenzohydrazide or 4-chlorobenzohydrazide (an equimolar amount) in absolute 
ethanol containing one drop of 37% hydrochloric acid. The mixture was stirred at room temperature 
for 2 hours until extensive precipitation was observed. Next, the solvent was partially concentrated at 
reduced pressure and the resulting mixture was poured into cold water. The precipitate formed was 
filtered out and dried under vacuum producing the desired (E,Z)-salicylaldehyde 2-chlorobenzoyl 
hydrazone (H2LASSBio-466) and (E)-salicylaldehyde 4-chlorobenzoyl hydrazone (H2LASSBio-1064) 
in 87% and 91% yield, respectively. The melting point and 1H-NMR data for both compounds were in 
agreement with previous reports [19,20]. 
3.3. Synthesis of Zinc(II) Complexes 
3.3.1. Synthesis of [Zn(LASSBio-466)H2O]2 (1) and [Zn(HLASSBio-1064)Cl]2 (2)  
Complexes 1 and 2 were obtained by mixing an ethanol solution of the desired hydrazone with zinc 
chloride and triethylamine in 1:1:1 ligand-to-metal-to-triethylamine molar ratio. The resulting solids 
were washed with ethanol followed by diethylether and then dried in vacuo.  
[Zn(LASSBio-466)H2O]2 (1). Yield 68%.Yellow solid. Anal. Calc. for C28H22N4O6Cl2Zn2 (712.18): C, 
47.26%; H, 2.85%; N, 7.40%. Found: C, 47.22%; H, 3.11%; N, 7.87%. M.P. > 300 °C. Molar 
conductivity: 8.23 Ω−1cm2 mol−1. IR: ν(C=N) 1614, ν(Zn-OH2) 1604, ν(phenolic, CO) 1329. 1H-
NMR: δ (ppm) = 7.54 (1H, H7), 7.47–7.59 (1H, H14), 7.52 (1H, H11), 7.51 (1H, H5), 7.44–7.47 (1H, 
H3), 7.32 (1H, H13), 7.28 (1H, H13), 6.79 (1H, H6), 6.70 (1H, H4). 13C-NMR: δ (ppm) = 169.73 (C8), 
158.02 (C1), 150.59(C7), 135.87 (C10), 135.09 (C12), 134.37 (C13), 131.38 (C5), 130.35 (C11), 
129.81 (C14), 127.48 (C3), 119.69 (C9, C2), 119.35 (C4), 118.37 (C6).  
[Zn(HLASSBio-1064)Cl]2 (2). Yield 71%. Yellow solid. Anal. Calc. for C28H20N4O4Cl4Zn2 (749.11): 
C, 44.72%; H, 2.24%; N, 7.10%. Found: C, 44.89%; H,2.69%; N, 7.48%. M.P. > 300 °C. Molar 
conductivity: 11.35 Ω−1cm2 mol−1. IR: ν(N-H) 3179, ν(C=O) 1618, ν(C=N) 1611, ν(phenolic, CO) 
1281. 1H-NMR: δ (ppm) = 8.99 (1H, H7), 8.01 (2H, H11,H13), 7.59 (2H, H10,H14), 7.38 (1H, H3), 
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7.24 (1H, H5), 6.73 (1H, H6), 6.89 (1H, H4). 13C-NMR: δ (ppm) = 168.88 (C8), 166.81 (C1), 155.61 
(C7), 136.83 (C12), 131.62 (C5), 129.68 (C10,C14), 129.58 (C3), 128.79 (C11, C13), 119.53 (C4), 
118.75 (C9, C2), 116.54 (C6).  
3.4. X-ray Crystallography 
The X-ray diffraction measurements were performed on an Enraf-Nonius Kappa-CCD 
diffractometer with graphite-monochromated MoKα (λ = 0.71073 Å) radiation. Diffraction data were 
collected (φ and ω scans with κ-offsets) with COLLECT [21]. Integration and scaling of the reflections 
were performed with HKL DENZO-SCALEPACK [22] suite of programs. The unit cell parameters 
were obtained by least-squares refinement based on the angular settings for all collected reflections 
using HKL SCALEPACK. The structure was solved by direct methods with SHELXS-97 [23] and the 
molecular model refined by full-matrix least-squares procedure on F2 with SHELXL-97 [24]. The 
hydrogen atoms were included in the molecular model at stereo-chemical positions and refined with 
the riding model. 
3.5. Anti-nociceptive and anti-inflammatory activities of H2LASSBio-466, H2LASSBio-1064, 
[Zn(LassBio-466)H2O]2 (1) and [Zn(HLassBio-1064)Cl]2 (2)  
3.5.1. Animals 
Experiments were conducted using Swiss mice obtained from the BIOCEN - UFAL breeding unit, 
weighing 20–30 g each, males or females, adult, with 6 to 8 weeks of age, distributed in groups of up 
to 6–8 animals for treatment. The animals were maintained with free access to food and water and kept 
at 25–28 °C under a controlled 12 h light·dark−1 cycle. All animals were manipulated according to the 
norms established by the Ethics Commission - UFAL for handling animals (protocol number: 
026681/2009-23). 
3.5.2. Writhing Test 
This test was performed as described by Collier and coworkers [14]. Acetic acid (0.6%, v/v) was 
administered i.p. in a volume of 0.1 mL·10 g−1. The number of writhes, a response consisting of 
contraction of an abdominal wall, pelvic rotation followed by hind limb extension, was counted during 
continuous observation for 20 min. beginning 5 min. after the acetic acid injection. The prototypes 
H2LASSBio-466, H2LASSBio-1064 and their zinc(II) complexes, indomethacin and dipyrone were 
administered at the dose of 100 µmol·kg−1 (p.o), 40 min. before the acetic acid injection. Control group 
received 10 mL·kg−1 of vehicle (arabic gum, p.o.). Anti-nociceptive activity was expressed as 
inhibition percentage of the usual number of writhing observed in control animals. 
3.5.3. Formalin-Induced Pain in Mice 
The formalin test was performed as described by Hunskaar and Hole [15]. Animals received 20 µL 
of a 2.5% formalin solution (0.92% formaldehyde in saline) in the ventral surface of the right hind 
paw. They were observed from 0 to 5 min. (neurogenic phase) and from 15 to 30 min. (inflammatory 
phase) after injection and the time they spent licking the injected paw was recorded and considered as 
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indicative of nociception. The prototypes H2LASSBio-466, H2LASSBio-1064, their zinc(II) 
complexes and indomethacin were administered at the dose of 100 µmol·kg−1 (p.o), 40 min. before 
formalin injection. Control group received 10 mL·kg−1 of vehicle (arabic gum, p.o.). 
3.5.4. Hot-Plate Test 
Mice were treated according to the method described by Eddy and Leimbach [16]. Each mouse was 
placed on the hot plate set at 54 ± 1.0 °C and the time of paw licking was recorded before and 30 min. 
after oral administration of the tested compounds. The prototypes H2LASSBio-466, H2LASSBio-1064 
and their zinc(II) complexes were administered at the dose of 100 µmol·kg−1 (p.o). Control group 
received 10 mL·kg−1 of vehicle (arabic gum, p.o.). Morphine was also used as a drug standard at the 
dose of 15 μmol·kg−1 (i.p.). Analgesia was defined as an increase in the latency of paw licking, and the 
latency times were compared with the values obtained for control. Sixty seconds were taken as the cut-
off time to avoid mouse tissue damage. 
3.5.5. Zymosan-Induced Peritonitis 
Peritoneal inflammation was induced according to the method described by Doherty [17]. A 
solution of zymosan A (Sigma-Aldrich, 2 mg·mL−1) was prepared in saline (0.9% NaCl) and injected 
into the peritoneal cavity of mice (0.5 mL). Six hours after injection of zymosan A, the animals were 
sacrificed by cervical dislocation and the peritoneal cavity was washed with cold Hank’s solution  
(3 mL). The prototypes H2LASSBio-466, H2LASSBio-1064, their zinc(II) complexes and 
indomethacin were administered at the dose of 100 µmol·kg−1 (p.o), 40 min. before zymosan A 
injection. The control group received 10 mL·kg−1 of vehicle (arabic gum, p.o.). The number of cells 
was quantified using an optical microscope, and a 100 x lens. 
3.5.6. Statistical Analysis 
Data obtained from animal experiments are represented by mean ± standard error of the mean 
(Mean ± S.E.M.). Statistical differences between the treated and the control groups were evaluated by 
test t of Student or ANOVA in the tutorial Prisma®. Values were considered significant if * P < 0.05, 
** P < 0.01 and *** P < 0.001. 
4. Conclusions 
The studied compounds, evaluated at a dose of 100 μmol/kg (p.o), showed marked inhibition of 
acetic acid-induced writhing response, with the anti-nociceptive activity being favored by zinc(II) 
complex formation in the case of complex 1. The compounds also have antinociception profile 
associated with inflammatory pain, with no activity in murine analgesic model of central pain. In the 
formalin model, H2LASSBio-466 was effective in inhibiting only the first phase, while its zinc(II) 
complex 1, like indomethacin, was active in the second phase, indicating its ability to inhibit 
nociception associated with inflammatory response. Hence coordination to zinc(II) altered the 
pharmacological profile of H2LASSBio-466. Moreover, the salicyladehyde N-acylhydrazone 
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derivatives and their zinc(II) complexes showed comparable or superior inhibition of cell-migration 
process to indomethacin, indicating an expressive anti-inflammatory profile. 
The different activities of the complexes could be explained by their releasing hydrazone at 
different rates during the assays. In addition, complex 1 contains a di-anionic hydrazone while 2 
contains a mono-anionic hydrazone. Hence different electronic effects could also influence the distinct 
pharmacological profiles of complexes 1 and 2. In addition, 1 contains a water molecule in the metal 
coordination sphere while 2 contains a chloride ion. Finally, coordination could in principle alter the 
bioavailability of the two hydrazones in different manners. The above-mentioned results suggest that 
further studies on the anti-inflammatory properties of this class of compounds and their zinc(II) 
complexes should be carried out in order to investigate their mechanism of action 
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